Literature DB >> 9854250

The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail.

J Shuter1, D D Fletcher, V J Simone, E Y Bellin.   

Abstract

PURPOSE: To determine the pharmacoeconomic impact of antimicrobial treatment of peptic ulcer disease (PUD) in a large urban jail. PATIENTS AND METHODS: Retrospective comparison of PUD-related pharmacy and laboratory expenditures over a 2-year period before and after the institution of a PUD treatment protocol with the priority of Helicobacter pylori eradication for inmates in Rikers Island Correctional Facility.
RESULTS: After the protocol was adopted, total pharmacy-related and laboratory-related expenses for PUD care decreased by 40.2%, and expenditures for ranitidine declined by 52.2%. There was an increase in spending for antimicrobial agents and H. pylori antibody testing, but this was insignificant compared to the savings generated by decreased ranitidine usage. Annual savings in our facility as a result of this intervention were $123,449.
CONCLUSIONS: Modern therapeutic strategies for PUD aimed at eradicating H. pylori can result in significant savings in the institutional setting; these savings are largely attributable to the decreased usage of histamine-2 receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854250      PMCID: PMC3456001          DOI: 10.1007/BF02344518

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  9 in total

Review 1.  Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.

Authors:  D A Peura; D Y Graham
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

Review 2.  NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease.

Authors: 
Journal:  JAMA       Date:  1994-07-06       Impact factor: 56.272

Review 3.  Endoscopy in the evaluation of dyspepsia. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

4.  Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.

Authors:  D Y Graham; G M Lew; P D Klein; D G Evans; D J Evans; Z A Saeed; H M Malaty
Journal:  Ann Intern Med       Date:  1992-05-01       Impact factor: 25.391

5.  Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.

Authors:  J J Sung; S C Chung; T K Ling; M Y Yung; V K Leung; E K Ng; M K Li; A F Cheng; A K Li
Journal:  N Engl J Med       Date:  1995-01-19       Impact factor: 91.245

6.  Alternative management strategies for patients with suspected peptic ulcer disease.

Authors:  A M Fendrick; M E Chernew; R A Hirth; B S Bloom
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

7.  Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications.

Authors:  K U Powell; G D Bell; G H Bolton; S M Burridge; A F Bowden; B Rameh; L Hart; P Bradley; G Harrison; P W Gant
Journal:  Q J Med       Date:  1994-05

Review 8.  The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.

Authors:  J H Walsh; W L Peterson
Journal:  N Engl J Med       Date:  1995-10-12       Impact factor: 91.245

9.  Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.

Authors:  S W Hosking; T K Ling; S C Chung; M Y Yung; A F Cheng; J J Sung; A K Li
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.